This section contains case studies, industry highlights, minireviews, and other articles for drug discovery professionals. Check out the resources page for posters, educational content, lists of drug approvals, and more.
The Merck LRRK2 inhibitor, MLi-2, is an orally available tool compound that is structurally distinct from the LRRK2 inhibitor GNE-7915.…
molecule
2 years ago ●
1 min read
The GSK αvβ6 integrin inhibitor, “compound 1,” or GSK 3008348 is a previously reported IPF clinical candidate that is a…
molecule
2 years ago ●
1 min read
The Takeda O-GlcNAcase (OGA) inhibitor, “compound 5i,” binds to the same site as prior sugar-based OGA inhibitors, but has surprisingly…
molecule
2 years ago ●
1 min read
The Eisai β-catenin/CBP inhibitor, E7386, is an orally active and selective inhibitor of the β-catenin/CBP protein-protein interaction, a key node…
molecule
2 years ago ●
1 min read
The Novartis BET bromodomain inhibitor, NVS-BET-1, is a new chemotype of BRD4 (BD1 and BD2) inhibitor. While we recently highlighted…
molecule
2 years ago ●
1 min read
The BMS HIV-1 maturation inhibitor, “compound 16,” is a potent derivative of the clinical candidate GSK3532795/955176, with double-digit nanomolar activity…
molecule
2 years ago ●
1 min read
Load More
